Articles related to PROSTATE CANCER

National Cancer Database data suggest that approximately half of prostate cancer focal therapy use from 2010 to 2023 occurred outside current guideline-supported settings, highlighting persistent gaps between clinical practice and available evidence.

Artificial intelligence tools are increasingly being integrated into prostate cancer imaging, pathology, prognostication, and treatment planning. Although several platforms have demonstrated promising accuracy and workflow benefits, broad clinical adoption will require prospective validation, regulatory oversight, and careful implementation.

Researchers identified a metabolic pathway in which amino acid breakdown generates propionyl-CoA, sustaining cholesterol production and androgen signaling in prostate cancer models. The findings suggest a potential mechanism of hormone therapy resistance, though clinical relevance remains unproven.

A Veterans Health Administration analysis of 4,890 men with metastatic hormone-sensitive prostate cancer found that achieving a PSA level below 0.2 ng/mL within 9 months was associated with improved survival. The retrospective findings support a threshold previously identified in clinical trials.

A randomized noninferiority trial involving 648 men with MRI-visible prostate lesions found that cognitive fusion biopsy achieved clinically significant prostate cancer detection rates similar to software-based fusion biopsy. Subgroup analyses suggested body mass index may influence the relative performance of each approach.

A two-year analysis of 12,670 screened men found that the Stockholm3 risk model detected more clinically significant prostate cancers than PSA testing alone, primarily through fewer false-negative results. The findings suggest improved screening discrimination, although follow-up remains limited to two years.